Therefore, the stemness marker (CD133), G2 phase marker (CDC2), anti-apoptosis marker (Bcl-2), and angiogenesis markers (HIF1A and VEGFA) were also detected and shown to be reduced with a decrease in the mesenchymal phenotype of GBM cells after NF treatment. The gene discussed is PROM1; the disease is glioblastoma.